Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

PURPOSE: Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of <4 months after first-line chemotherapy. No standard targeted therapies are available. We present the preclinical character...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Chawla, Sant P., Conley, Anthony P., Wilky, Breelyn A., Tolcher, Anthony, Lakhani, Nehal J., Berz, David, Andrianov, Vasily, Crago, William, Holcomb, Monica, Hussain, Abrahim, Veldstra, Carson, Kalabus, James, O’Neill, Brianne, Senne, Lane, Rowell, Emily, Heidt, Analeah B., Willis, Katelyn M., Eckelman, Brendan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425732/
https://www.ncbi.nlm.nih.gov/pubmed/37265425
http://dx.doi.org/10.1158/1078-0432.CCR-23-0974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425732/
https://www.ncbi.nlm.nih.gov/pubmed/37265425
http://dx.doi.org/10.1158/1078-0432.CCR-23-0974

Ejemplares similares